[
  {
    "ts": "2025-10-17T07:19:50+00:00",
    "headline": "What Catalysts Could Shift the Narrative for Abbott as Analysts Weigh New Developments",
    "summary": "Abbott Laboratories' consensus analyst price target has seen a modest uptick, increasing from $142.48 to $144.40 following the company’s latest earnings update. This change reflects a blend of ongoing optimism about Abbott’s medical device growth and robust international presence, as well as some lingering concerns over near-term challenges. Stay tuned to discover how you can track these evolving perspectives and remain informed about Abbott’s shifting investment outlook. What Wall Street Has...",
    "url": "https://finance.yahoo.com/news/catalysts-could-shift-narrative-abbott-071950284.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8c389366-91f2-3746-a771-7c8832b52ee4",
      "content": {
        "id": "8c389366-91f2-3746-a771-7c8832b52ee4",
        "contentType": "STORY",
        "title": "What Catalysts Could Shift the Narrative for Abbott as Analysts Weigh New Developments",
        "description": "",
        "summary": "Abbott Laboratories' consensus analyst price target has seen a modest uptick, increasing from $142.48 to $144.40 following the company’s latest earnings update. This change reflects a blend of ongoing optimism about Abbott’s medical device growth and robust international presence, as well as some lingering concerns over near-term challenges. Stay tuned to discover how you can track these evolving perspectives and remain informed about Abbott’s shifting investment outlook. What Wall Street Has...",
        "pubDate": "2025-10-17T07:19:50Z",
        "displayTime": "2025-10-17T07:19:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7zJOBZ6wPnYKbKPRmWh.qQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc9EgsXKjWnUzlOQpxWhqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/catalysts-could-shift-narrative-abbott-071950284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/catalysts-could-shift-narrative-abbott-071950284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]